Menu Search
Equities

DURECT Corp

DRRX:NAQ

DURECT Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.925
  • Today's Change0.062 / 7.23%
  • Shares traded98.08k
  • 1 Year change+42.31%
  • Beta1.0421
Data delayed at least 15 minutes, as of Nov 22 2024 15:49 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year DURECT Corp had revenues fall -55.67% from 19.28m to 8.55m, though the company grew net income from a loss of 35.33m to a smaller loss of 27.62m.
Gross margin78.87%
Net profit margin-198.62%
Operating margin-225.06%
Return on assets-43.33%
Return on equity-218.51%
Return on investment-156.35%
More ▼

Cash flow in USDView more

In 2023, cash reserves at DURECT Corp fell by 15.08m. Cash Flow from Financing totalled 20.50m or 239.79% of revenues. In addition the company used 34.41m for operations while cash used for investing totalled 1.17m.
Cash flow per share-0.5603
Price/Cash flow per share--
Book value per share0.0392
Tangible book value per share-0.1595
More ▼

Balance sheet in USDView more

DURECT Corp has a Debt to Total Capital ratio of 89.58%.
Current ratio0.7139
Quick ratio0.5963
Total debt/total equity8.60
Total debt/total capital0.8958
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.